Stephanie Tcherny-Lessenot

Global Head of Benefit-Risk Evaluation - Sanofi

Head of Benefit-Risk evaluation, Global Pharmacovigilance, Sanofi Research & Development


Stephanie, public health physician, has over 18 years of experience working in pharma companies on Pharmacoepidemiology and BR evaluation to support market access, pricing and risk management plans. After her appointments at Eli Lilly, she joined Global Pharmacovigilance & Epidemiology department at Sanofi in 2010 as a Global Pharmacoepidemiologist, as a Pharmacoepidemiology Lead in 2016 and Head of BenefitRisk evaluation in 2017. Stephanie is one of the leading experts in the qualitative and quantitative BR field and has conducted many benefit-risk analyses for development and marketed drugs for over 11 years.

Stephanie Tcherny-Lessenot


  • Wednesday - November 23, 2022 - 14:25

    Panel Discussion – The future of pharmacovigilance: How technology will change the way we monitor drugs

    • The future of pharmacovigilance will be more automated
    • AI will play a big role in data management and analysis
    • The use of technology will increase speed and accuracy

      Watch Session


Stay Informed

Subscribe today to receive news on latest updates,
offers and upcoming conferences via email

For general conference and registration enquires please contact the below email id or fill out the form

Enquire now